CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy

Detalles Bibliográficos
Autores principales: Ramachandran, Raja, Yadav, Ashok K., Kumar, Vinod, Gupta, Krishan L., Kohli, Harbir S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678839/
https://www.ncbi.nlm.nih.gov/pubmed/29142946
http://dx.doi.org/10.1016/j.ekir.2016.08.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678839/
https://www.ncbi.nlm.nih.gov/pubmed/29142946
http://dx.doi.org/10.1016/j.ekir.2016.08.019

Ejemplares similares